Growth factors for treating diabetic foot ulcers

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 10, 2015, Pages

  Martí Carvajal, Arturo J ^a   Gluud, Christian ^b   Nicola, Susana ^c   Simancas Racines, Daniel ^c   Reveiz, Ludovic ^d   Oliva, Patricio ^e   Cedeño Taborda, Jorge ^f  

^a Iberoamerican Cochrane Network   (Venezuela)

^b Rigshospitalet   (Denmark)

^c School of Engineering Sciences and Industry   (Ecuador)

^d Free time independent Cochrane reviewer   (United States)

^e UNIVERSIDAD DEL DESARROLLO   (Chile)

^f UNIVERSIDAD DE CARABOBO   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; DERMAGEN; GROWTH FACTOR; LACTOFERRIN; PEPTIDE DERIVATIVE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT ACIDIC FIBROBLAST GROWTH FACTOR; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT LACTOFERRIN; RECOMBINANT PROTEIN; RECOMBINANT VASCULOTROPIN; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; GROWTH PROMOTOR;

DIABETIC FOOT; DRUG INDUSTRY; DRUG WITHDRAWAL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LEG AMPUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TOPICAL TREATMENT; WOUND HEALING; AMPUTATION; COMPLICATION; META ANALYSIS;

AMPUTATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; GROWTH SUBSTANCES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WOUND HEALING;

EID: 84962130435     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008548.pub2     Document Type: Review

References (183)

1. Afshari M, Larijani B, Fadayee M, Ghahary A, Pajouhi M, Bastanhagh M, et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy 2005;2:759-65.
2. Agrawal RP, Jhajharia A, Motha N, Dogra R, Chaudhari V, Nayak KC. Use of a platelet-derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot Journal 2009;12(2):80-8.
3. Bhansali A, Venkatesh S, Dutta P, Dhillon MS, Das S, Agrawal A. Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?. Diabetes Research and Clinical Practice 2009;83(1):e13-6.
4. Chen A, Long XH, Huang C. Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot. Modern Nursing 2004;10(3):274-5.
5. d'Hemecourt PA, Smeill JM, Hugill JV, Prigoff MM. The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23-27 August 1997:Abstracts.
6. d'Hemecourt PA, Smiell JM, Karim MR. Sodium carboxymethyl cellulose aqueous-based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds 1998;10(3):69-75.
7. Driver VR. A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non-healing diabetic foot ulcers. Diabetes 2006;55(Suppl 1):A25.
8. Driver VR, Hanft J, Fylling CP, Beriou JM, AutoGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management 2006;52(6):68-87.
9. Fernández-Montequin JI, Infante-Cristia E, Valenzuela-Silva C, Franco-Perez N, Savigne-Gutierrez W, Artaza-Sanz H, et al. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal 2007;4:333-43.
10. Fernández-Montequín JI, Betancourt BY, Leyva-Gonzalez G, Mola EL, Galán-Naranjo K, Ramírez-Navas M, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal 2009;6:67-72.
11. Fernández-Montequín JI, Valenzuela-Silva CM, Díaz OG, Savigne W, Sancho-Soutelo N, Rivero-Fernández F, Cuban Diabetic Foot Study Group. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. International Wound Journal 2009;6:432-43.
12. Hanft JR, Pollak RA, Barbul A, van Gils C, Kwon PS, Gray SM, et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care 2008;17:30-2, 34-7.
13. Kwon P, Breen TJ, Gray S, Lynch CJ, Semba CP, Hanft JR, et al. Results of a phase I, randomized, double-blind, placebo-controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management 2006;54:102.
14. Hardikar JV, Reddy YC, Bung DD, Varma N, Shilotri PP, Prasad ED, et al. Efficacy of recombinant human platelet-derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double-blind, placebo-controlled study in India. Wounds 2005;17:141-52.
15. Holloway GA, Steed DL, DeMarco MJ, Matsumoto T, Moosa HH, Webster MW, et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT-102 in chronic, non healing diabetic wounds. Wounds 1993;5:198-206.
16. Jaiswal SS, Gambhir RPS, Harish AA. Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery 2010;72:31-5.
17. Kakagia DD, Kazakos KJ, Xarchas KC, Karanikas M, Georgiadis GS, Tripsiannis G, et al. Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and its Complications 2007;21:387-91.
18. Landsman A, Agnew P, Parish L, Joseph R, Galiano RD. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis. Journal of the American Podiatric Medical Association 2010;100(3):155-60.
19. Parish L, Routh H, Parish J. Diabetic foot ulcers: a randomized multicenter study comparing a moisture-controlling dressing with a topical growth factor. Journal of the American Academy of Dermatology 2009;60(Suppl):AB202.
20. Lyons TE, Miller MS, Serena T, Sheehan P, Lavery L, Kirsner RS, et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery 2007;193(1):49-54.
21. Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care 2005;18:258-66.
22. Richard JL, Parer-Richard C, Daures JP, Clouet S, Vannereau D, Bringer J, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care 1995;18:64-9.
23. Robson MC, Steed DL, McPherson JM, Pratt BM. Effects of transforming growth factor +2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose-ranging trial. Journal of Applied Research 2002;2:133-45.
24. Saldalamacchia G, Lapice E, Cuomo V, De Feo E, D'Agostino E, Rivellese AA, et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutrition Metabolism and Cardiovascular Diseases 2004;14:395-6.
25. Saldalamacchia G, Lapice E, Cuomo V, De Feo ME, D'Agostino E, Rivellese AA, et al. Use of autologous platelet gel for the treatment of diabetic foot ulcers. Giornale Italiano di Diabetologia e Metabolismo 2004;24:103-5.
26. Steed D, Goslen JB, Holloway GA, Malone JM, Bunt TJ, Webster MW. Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care 1992;15:1598-604.
27. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery 2006;117 (Suppl7):143-9.
28. Steed DL, Webster MW, Ricotta JJ, Luterman A, Brown S, Comerota AJ, et al. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery 1995;21:71-81.
29. Steed D, Ricotta JJ, Prendergast JJ, Kaplan RJ, Webster MW, McGill JB, et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine-aspartic acid (RGD) peptide matrix. Diabetes Care 1995;18:39-46.
30. Steed DL, Edington HD, Webster MW. Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. Wound Repair and Regeneration 1996;4:230-3.
31. Tan Y, Xiao J, Huang Z, Xiao Y, Lin S, Jin L, et al. Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients. Journal of Health Science 2008;54:432-40.
32. Tsang MW, Wong WK, Hung CS, Lai KM, Tang W, Cheung EY, et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003;26:1856-61.
33. Uchi H, Igarashi A, Urabe K, Koga T, Nakayama J, Kawamori R, et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology 2009;19:461-8.
34. Viswanathan V, Pendsey S, Sekar N, Murthy GSR. A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-D 150) in healing diabetic foot ulcers. Wounds 2006;18:186-96.
35. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998;21(5):822-7.
36. Acosta JB, Savigne W, Valdez C, Franco N, Alba JS, del Rio A, et al. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. International Wound Journal 2006;3(3):232-9.
37. Aminian B, Shams M, Soveyd M, Omrani GhR. Topical autologous platelet-derived growth factors in the treatment of chronic diabetes ulcers. Archives of Iranian Medicine 2000; Vol. 3, issue 2:55-9.
38. Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, The Canadian Becaplermin Study Group. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy. Wound Repair and Regeneration 2000;8:162-8.
39. Hong JP, Jung HD, Kim YW. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Annals of Plastic Surgery 2006;56:394-8.
40. Miller MS. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers. The Journal of Foot and Ankle Surgery 1999;38:227-31.
41. Mohan VK. Recombinant human epidermal growth factor (REGEN-D 150): effect on healing of diabetic foot ulcers. Diabetes Research and Clinical Practice 2007;78:405-11.
42. Saad Setta H, Elshahat A, Elsherbiny K, Massoud K, Safe I. Platelet-rich plasma versus platelet-poor plasma in the management of chronic diabetic foot ulcers: a comparative study. International Wound Journal 2011;8(3):307-12.
43. Tuyet HL, Quynh TTN, Minh HVH, Bich DNT, Dinh TD, Tan DL, et al. The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results. International Wound Journal 2009;6:159-66.
44. Yera-Alos IB, Alonso-Carbonell L, Valenzuela-Silva CM, Tuero-Iglesias AD, Moreira-Martinez M, Marrero-Rodriguez I, et al. Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers. BMC Pharmacology and Toxicology 2013;14:44.
45. Gomez-Villa R, Aguilar-Rebolledo F, Lozano-Platonoff A, Teran-Soto JM, Fabian-Victoriano MR, Kresch-Tronik NS, et al. Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: a randomized double-blinded controlled trial. Wound Repair and Regeneration 2014;22(4):497-503.
46. Morimoto N, Yoshimura K, Niimi M, Ito T, Aya R, Fujitaka J, et al. Novel collagen/gelatin scaffold with sustained release of basic fibroblast growth factor: clinical trial for chronic skin ulcers. Tissue engineering 2013 Part A;19(17-18):1931-40.
47. Singla S, Garg R, Kumar A, Gill C. Efficacy of topical application of beta urogastrone (recombinant human epidermal growth factor) in Wagner's Grade 1 and 2 diabetic foot ulcers: Comparative analysis of 50 patients. Journal of Natural Science, Biology and Medicine 2014;5(2):273-7.
48. Young MJ, Larsen J, Knowles A, Parnell L, Ward JD. The treatment of diabetic neuropathic foot ulcers with biosynthetic platelet derived growth factor. Diabetic Medicine 1992, (Suppl 2):S42.
49. NCT00521937. Efficacy and Safety Study of DERMAGEN® vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer. https://clinicaltrials.gov/ct2/show/NCT00521937.
50. NCT00709514. Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers. https://clinicaltrials.gov/ct2/show/NCT00709514.
51. NCT00915486. A Dose Finding Study of Topically Applied I-020201 as an Adjunct to Good Standard-of-care in Patients With Chronic Diabetic Foot Ulcers (DFU). https://clinicaltrials.gov/ct2/show/NCT00915486.
52. NCT00926068. Safety and Efficacy of HO/03/03 10μg in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers (Truheal). https://clinicaltrials.gov/ct2/show/NCT00926068.
53. NCT01060670. A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers. https://clinicaltrials.gov/ct2/show/NCT01060670.
54. NCT01098357. Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer. https://clinicaltrials.gov/ct2/show/NCT01098357.
55. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, et al. North-West Diabetes Foot Care Study. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabetes Medicine 2002;19:377-84.
56. Albert S. Cost-effective management of recalcitrant diabetic foot ulcers. Clinics in Podiatric Medicine and Surgery 2002;19:483-91.
57. Ali S, Fareed A, Humail S, Basit A, Ahmedani M, Fawwad A, et al. The personal cost of diabetic foot disease in the developing world -a study from Pakistan. Diabetic Medicine 2008; Vol. 25:1231-3.
58. Amery CM. Growth factors and the management of the diabetic foot. Diabetic Medicine 2005;22 Suppl 1:12-4.
59. Andersen JH. Technology evaluation: rh lactoferrin, Agennix. Current Opinion in Molecular Therapeutics 2004;6(3):344-9.
60. Armstrong DG, Lavery LA, Wrobel JS, Vileikyte L. Quality of life in healing diabetic wounds: does the end justify the means?. Journal of Foot and Ankle Surgery 2008;47:278-82.
61. Ashry HR, Lavery LA, Armstrong DG, Lavery DC, van Houtum WH. Cost of diabetes-related amputations in minorities. The Journal of Foot and Ankle Surgery 1998;37:186-90.
62. Bakker K, Schaper NC. The development of global consensus guidelines on the management and prevention of the diabetic foot 2011. Diabetes/Metabolism Research and Reviews 2012;28(Suppl 1):116-8.
63. Bakker K, Apelqvist J, Schaper NC. Practical guidelines on the management and prevention of the diabetic foot 2011. Diabetes/Metabolism Research and Reviews 2012;28(Suppl 1):225-31.
64. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6.
65. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair and Regeneration 2008;16:585-601.
66. Bartus CL, Margolis DJ. Reducing the incidence of foot ulceration and amputation in diabetes. Current Diabetes Reports 2004;4:413-8.
67. Basch E, Aronson N, Berg A, Flum D, Gabriel S, Goodman SN, et al. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA 2012;307(15):1636-40.
68. Beckert S, Witte M, Wicke C, Königsrainer A, Coerper S. A new wound-based severity score for diabetic foot ulcers: a prospective analysis of 1, 000 patients. Diabetes Care 2006;29:988-92.
69. Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL. Growth factors in the treatment of diabetic foot ulcers. The British Journal of Surgery 2003;90:133-46.
70. Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Reviews 2009;23(4):177-89.
71. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005;366:1719-24.
72. Boulton AJ. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes/Metabolism Research and Reviews 2008;24 (Suppl 1):3-6.
73. Boutoille D, Féraille A, Maulaz D, Krempf M. Quality of life with diabetes-associated foot complications: comparison between lower-limb amputation and chronic foot ulceration. Foot and Ankle International 2008;29:1074-8.
74. Buchberger B, Follmann M, Freyer D, Huppertz H, Ehm A, Wasem J. The importance of growth factors for the treatment of chronic wounds in the case of diabetic foot ulcers. GMS Health Technology Assessment 2010;6:Doc12.
75. Buchmayer F, Pleiner J, Elmlinger MW, Lauer G, Nell G, Sitte HH. Actovegin(R): a biological drug for more than 5 decades. Wiener Medizinische Wochenschrift 2011;161(3-4):80-8.
76. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586.
77. Chao CY, Cheing GL. Microvascular dysfunction in diabetic foot disease and ulceration. Diabetes/Metabolism Research and Reviews 2009;25:604-14.
78. Clarke M. Standardising outcomes for clinical trials and systematic reviews. Trials 2007;8:39.
79. Comprehensive Meta-Analysis team. Comprehensive Meta-Analysis Sofware. 2.2.064. Englewood, NJ: Biostat, Inc, 2011.
80. Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD006810]
81. Enoch S, Leaper DJ. Basic science of wound healing. Surgery 2008;26(2):31-7.
82. Food, Drug Administration. Regranex (becaplermin) Gel. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm094968.htm (accessed 6 July 2011).
83. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Reviews in Endocrine & Metabolic Disorders 2008;9:301-14.
84. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. The American Journal of Sports Medicine 2009;37(11):2259-72.
85. Gabriel SE, Normand SL. Getting the methods right -the foundation of patient-centered outcomes research. The New England Journal of Medicine 2012;367(9):787-90.
86. Galkowska H, Wojewodzka U, Olszewski WL. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair and Regeneration 2006;14:558-65.
87. Girod I, Valensi P, Laforêt C, Moreau-Defarges T, Guillon P, Baron F. An economic evaluation of the cost of diabetic foot ulcers: results of a retrospective study on 239 patients. Diabetes and Metabolism 2003;29:269-77.
88. Goodridge D, Trepman E, Sloan J, Guse L, Strain LA, McIntyre J, et al. Quality of life of adults with unhealed and healed diabetic foot ulcers. Foot and Ankle International 2006;27:274-80.
89. Grazul-Bilska AT, Johnson ML, Bilski JJ, Redmer DA, Reynolds LP, Abdullah A, et al. Wound healing: the role of growth factors. Drugs of Today 2003;39:787-800.
90. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64(4):380-2.
91. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction -GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
92. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395-400.
93. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence -study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15.
94. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence -publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82.
95. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence -imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93.
96. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence -inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302.
97. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence -indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10.
98. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311-6.
99. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66(2):151-7.
100. Habib SH, Biswas KB, Akter S, Saha S, Ali L. Cost-effectiveness analysis of medical intervention in patients with early detection of diabetic foot in a tertiary care hospital in Bangladesh. Journal of Diabetes and its Complications 2010;24(4):259-64.
101. Herber OR, Schnepp W, Rieger MA. A systematic review on the impact of leg ulceration on patients' quality of life. Health and Quality of Life Outcomes 2007;25:44.
102. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
103. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org.
104. Hinchliffe RJ, Valk GD, Apelqvist J, Armstrong DG, Bakker K, Game FL, et al. A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes/Metabolism Research and Reviews 2008;24(Suppl 1):119-44.
105. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670-4.
106. Humphrey AR, Dowse GK, Thoma K, Zimmet PZ. Diabetes and nontraumatic lower extremity amputations. Incidence, risk factors, and prevention -a 12-year follow-up study in Nauru. Diabetes Care 1996;19:710-4.
107. International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
108. Ince P, Kendrick D, Game F, Jeffcoate W. The association between baseline characteristics and the outcome of foot lesions in a UK population with diabetes. Diabetic Medicine 2007;24:977-81.
109. Ince P, Abbas ZG, Lutale JK, Basit A, Ali SM, Chohan F, et al. Use of the SINBAD classification system and score in comparing outcome of foot ulcer management on three continents. Diabetes Care 2008;31:964-7.
110. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781-8.
111. Ioannidis JP. Meta-research: the art of getting it wrong. Research Synthesis Methods 2010;1(3-4):169-84.
112. Iversen MM, Midthjell K, Østbye T, Tell GS, Clipp E, Sloane R, et al. History of and factors associated with diabetic foot ulcers in Norway: the Nord-Trøndelag Health Study. Scandinavian Journal of Public Health 2008;36:62-8.
113. Izumi Y, Satterfield K, Lee S, Harkless LB, Lavery LA. Mortality of first-time amputees in diabetics: a 10-year observation. Diabetes Research and Clinical Practice 2009;83(1):126-31.
114. Jeffcoate WJ, Harding KG. Diabetic Foot Ulcers. Lancet 2003;361:1545-51.
115. Jeffcoate WJ, van Houtum WH. Amputation as a marker of the quality of foot care in diabetes. Diabetologia 2004;47:2051-8.
116. Jeffcoate WJ. The incidence of amputation in diabetes. Acta Chirurgica Belgica 2005;105:140-2.
117. Kanade R, Van Deursen R, Burton J, Davies V, Harding K, Price P. Re-amputation occurrence in the diabetic population in South Wales, UK. International Wound Journal 2007;4:344-52.
118. Kinmond K, McGee P, Gough S, Ashford R. 'Loss of self': a psychosocial study of the quality of life of adults with diabetic foot ulceration. Journal of Tisssue Viability 2003;13:6-8, 10, 12.
119. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365.
120. Köveker GB. Growth factors in clinical practice. International Journal of Clinical Practice 2000;54:590-3.
121. Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. The Yale Journal of Biology and Medicine 2010;83(1):1-9.
122. Lantis JC 2nd, Boone D, Gendics C, Todd G. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer. Advances in Skin and Wound Care 2009;22:167-71.
123. Lavery LA, Armstrong DG, Harkless LB. Classification of diabetic foot wounds. The Journal of Foot and Ankle Surgery 1996;35:528-31.
124. Lavery LA, Peters EJ, Williams JR, Murdoch DP, Hudson A, Lavery DC, International Working Group on the Diabetic Foot. Reevaluating the way we classify the diabetic foot: restructuring the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. Diabetes Care 2008;31:154-6.
125. Lavery LA, Peters EJ, Armstrong DG, Wendel CS, Murdoch DP, Lipsky BA. Risk factors for developing osteomyelitis in patients with diabetic foot wounds. Diabetes Research and Clinical Practice 2009;83:347-52.
126. Lee JS, Lu M, Lee VS, Russell D, Bahr C, Lee ET. Lower-extremity amputation. Incidence, risk factors, and mortality in the Oklahoma Indian Diabetes Study. Diabetes 1993;42:876-82.
127. Lefebvre C, Manheimer E, Glanville J, on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
128. Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Risk factors predicting lower extremity amputations in patients with NIDDM. Diabetes Care 1996;19:607-12.
129. Leymarie F, Richard JL, Malgrange D. Factors associated with diabetic patients at high risk for foot ulceration. Diabetes and Metabolism 2005;31:603-5.
130. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections. Clinical Infectious Disease 2004;39:885-910.
131. McKinney M. 'Time is of the essence'. PCORI moves to implement comparative effectiveness research, funding. Modern Healthcare 2012; Vol. 42, issue 5:12-3.
132. Meatherall BL, Garrett MR, Kaufert J, Martin BD, Fricke MW, Arneja AS, et al. Disability and quality of life in Canadian aboriginal and non-aboriginal diabetic lower-extremity amputees. Archives of Physical Medicine and Rehabilitation 2005;86:1594-602.
133. Milman MHSA, Leme CBM, Borelli DT, Kater FR, Baccili ECDC, Rocha RCM, et al. Diabetic foot: evaluation of evolution and hospital cost of hospitalized patients in Conjunto Hospitalar de Sorocaba. Arquivos Brasileiros de Endocrinologia e Metabologia 2001;45:447-51.
134. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
135. Moss SE, Klein R, Klein BE. Long-term incidence of lower-extremity amputations in a diabetic population. Archives of Family Medicine 1996;5:391-8.
136. Nabuurs-Franssen MH, Huijberts MS, Nieuwenhuijzen Kruseman AC, Willems J, Schaper NC. Health-related quality of life of diabetic foot ulcer patients and their caregivers. Diabetologia 2005;48:1906-10.
137. Nelson RG, Gohdes DM, Everhart JE, Hartner JA, Zwemer FL, Pettitt DJ, et al. Lower-extremity amputations in NIDDM. 12-year follow-up study in Pima Indians. Diabetes Care 1988;11:8-16.
138. O'Meara S, Cullum N, Majid M, Sheldon T. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technology Assessment 2000;4(21):1-237.
139. Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Armstrong DG, Harkless LB. The effects of ulcer size and site, patient's age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. Diabetic Medicine 2001;18:133-8.
140. Papanas N, Maltezos E. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises?. The International Journal of Lower Extremity Wounds 2007;6:37-53.
141. Papanas N, Maltezos E. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clinical Interventions in Aging 2008;3:233-40.
142. Papanas N, Maltezos E. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Safety 2010;33(6):455-61.
143. Patient-Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: 'Our questions, our decisions: Standards for patient-centered outcomes research'. http://www.pcori.org/assets/Preliminary-Draft-Methodology-Report.pdf (accessed 2 August 2012).
144. Porta M. A Dictionary of Epidemiology. Fifth. New York: Oxford University Press, 2008.
145. Pradhan L, Nabzdyk C, Andersen ND, LoGerfo FW, Veves A. Inflammation and neuropeptides: the connection in diabetic wound healing. Expert Reviews in Molecular Medicine 2009;11:e2.
146. Price P. The diabetic foot: quality of life. Clinical Infectious Diseases 2004;39(Suppl 2):129-31.
147. Quattrini C, Jeziorska M, Boulton AJ, Malik RA. Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy. Diabetes Care 2008;31:140-5.
148. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999;22:382-7.
149. Rathur HM, Boulton AJ. The diabetic foot. Clinics in Dermatology 2007;25:109-20.
150. Redekop WK, Stolk EA, Kok E, Lovas K, Kalo Z, Busschbach JJ. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes and Metabolism 2004;30:549-56.
151. Ribu L, Birkeland K, Hanestad BR, Moum T, Rustoen T. A longitudinal study of patients with diabetes and foot ulcers and their health-related quality of life: wound healing and quality-of-life changes. Journal of Diabetes Complications 2008;22:400-7.
152. Richard JL, Schuldiner S. Epidemiology of diabetic foot problems [Épidémiologie du pied diabétique]. La Revue Médicine Interne 2008;29(Suppl 2):222-30.
153. Rith-Najarian SJ, Stolusky T, Gohdes DM. Identifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting. A prospective evaluation of simple screening criteria. Diabetes Care 1992;15:1386-9.
154. Rozman P, Bolta Z. Use of platelet growth factors in treating wounds and soft-tissue injuries. Acta Dermatovenerologica Alpina, Panonica, et Adriatica 2007;16(4):156-65.
155. Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes/Metabolism Research and Reviews 2004;20(Suppl 1):90-5.
156. Schaper NC, Apelqvist J, Bakker K. Reducing lower leg amputations in diabetes: a challenge for patients, healthcare providers and the healthcare system. Diabetologia 2012;55(7):1869-72.
157. Schaper NC, Andros G, Apelqvist J, Bakker K, Lammer J, Lepantalo M, et al. Diagnosis and treatment of peripheral arterial disease in diabetic patients with a foot ulcer. A progress report of the International Working Group on the Diabetic Foot. Diabetes/Metabolism Research and Reviews 2012;28(Suppl 1):218-24.
158. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology 2010;63(8):834-40.
159. Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA 2012;307(15):1583-4.
160. Sheehan P, Jones P, Giurini JM, Caselli A, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Plastic and Reconstructive Surgery 2006;117(7 Suppl):239-44.
161. Sibbald RG, Woo KY. The biology of chronic foot ulcers in persons with diabetes. Diabetes/Metabolism Research and Reviews 2008;24(Suppl 1):25-30.
162. Scottish Intercollegiate Guidelines Network (SIGN). Search filters. http://www.sign.ac.uk/methodology/filters.html#random (accessed 12 March 2010).
163. Siriwardana HD, Weerasekera D. The cost of diabetic foot conditions. The Ceylon Medical Journal 2007;52:89-91.
164. Skoutas D, Papanas N, Georgiadis GS, Zervas V, Manes C, Maltezos E, et al. Risk factors for ipsilateral reamputation in patients with diabetic foot lesions. The International Journal of Lower Extremity Wounds 2009;8:69-74.
165. Smith D, Cullen MJ, Nolan JJ. The cost of managing diabetic foot ulceration in an Irish hospital. Irish Journal of Medical Science 2004;173:89-92.
166. Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, et al. Platelet functions beyond hemostasis. Journal of Thrombosis and Haemotasis 2009;7(11):1759-66.
167. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
168. Szabo C. Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. British Journal of Pharmacology 2009;156:713-27.
169. Valensi P, Girod I, Baron F, Moreau-Defarges T, Guillon P. Quality of life and clinical correlates in patients with diabetic foot ulcers. Diabetes and Metabolism 2005;31(3 Pt 1):263-71.
170. Van Acker K, Oleen-Burkey M, De Decker L, Vanmaele R, Van Schil P, Matricali G, et al. Cost and resource utilization for prevention and treatment of foot lesions in a diabetic foot clinic in Belgium. Diabetes Research and Clinical Practice 2000;50:87-95.
171. Van Houtum WH. Amputations and ulceration; pitfalls in assessing incidence. Diabetes/Metabolism Research and Reviews 2008;24(Suppl 1):14-8.
172. Veves A, Murray HJ, Young MJ, Boulton AJ. The risk of foot ulceration in diabetic patients with high foot pressure: a prospective study. Diabetologia 1992;35:660-3.
173. Viswanathan V, Thomas N, Tandon N, Asirvatham A, Rajasekar S, Ramachandran A, et al. Profile of diabetic foot complications and its associated complications -a multicentric study from India. The Journal of Association Physicians of India 2005;53:933-6.
174. TM 150) in healing diabetic foot ulcers. Wounds 2006;18:186-96.
175. Wagner FW. The dysvascular foot: a system of diagnosis and treatment. Foot and Ankle International 1981;2:64-122.
176. Weinberg ED. The therapeutic potential of lactoferrin. Expert Opinion on Investigational Drugs 2003;12(5):841-51.
177. Wieman TJ. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group. American Journal of Surgery 1998;176(2A Suppl):74S-9S. [PUBMED: 9777976]
178. Willrich A, Pinzur M, McNeil M, Juknelis D, Lavery L. Health related quality of life, cognitive function, and depression in diabetic patients with foot ulcer or amputation. A preliminary study. Foot and Ankle International 2005;26:128-34.
179. Winkley K, Stahl D, Chalder T, Edmonds ME, Ismail K. Risk factors associated with adverse outcomes in a population-based prospective cohort study of people with their first diabetic foot ulcer. Journal of Diabetes and its Complications 2007;21:341-9.
180. Younes NA, Albsoul AM, Awad H. Diabetic heel ulcers: a major risk factor for lower extremity amputation. Ostomy/Wound Management 2004;50:50-60.
181. Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 1994;17:557-60.
182. Zavala D, Martí-Carvajal A, Peña-Marti G, Comunián-Carrasco G. Software for data transformation for time-to-event outcomes (alfa version). Valencia: Universidad de Carabobo, 2007.
183. Ziyadeh N, Fife D, Walker AM, Wilkinson GS, Seeger JD. A matched cohort study of the risk of cancer in users of becaplermin. Advances in Skin and Wound Care 2011;24(1):31-9.